Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Clasificación en acciones #33640
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Precio por acción
$0.03702159
Última sincronización: 2024-01-29
Capitalización bursátil
$7.21M
Cambio (1 día)
-3.08%
Cambio (1 año)
0.00%
País
AU
Comercio Antisense Therapeutics Limited (ANP)

Categoría

Ratio P/B de Antisense Therapeutics Limited (ANP)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Antisense Therapeutics Limited, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Antisense Therapeutics Limited desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras